88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy HONG KONG , June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed ... 2026-06-15T Health Care/Hospital Medical/Pharmaceuticals
VARON Encourages Oxygen Users to Enjoy Soccer Season with Confidence at Home and On the Go NEW YORK , June 14, 2026 /PRNewswire/ -- Soccer season brings excitement, community, and unforgettable moments for millions of fans worldwide. Whether gathering with family to watch a match at home, ... 2026-06-15T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals Retail
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce ... 2026-06-15T Health Care/Hospital Medical/Pharmaceuticals
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026 Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients A manageable safety profile, with prolonged disease control and ... 2026-06-15T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware ... 2026-06-15T Health Care/Hospital Medical/Pharmaceuticals
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm ... 2026-06-14T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Global Heart Hub finds women delay seeking heart care by continuing to put others first Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals. Findings were presented at the European Society of Cardiology's ACNAP ... 2026-06-13T Health Care/Hospital Medical/Pharmaceuticals
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis SHANGHAI , June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly ... 2026-06-12T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio HONG KONG , June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111) , the company's internally-developed ... 2026-06-12T Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , June 12, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the ... 2026-06-12T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved